GroEL1 decreases EPC number and function. by Yi-Wen Lin (143406)

CXCL8 release is decreased in particulate laden macrophages. by Jamie Rylance (396383)

Negativity ratings (mean ± SE) during <i>attend/negative</i> trials (left) and <i>decrease/negative</i> trials (right) of the emotion regulation task, in the TSD (red) and WR (blue... by Anthony R. Stenson (11378981)

Image_5_A Non-destructive Method to Quantify Leaf Starch Content in Red Clover.JPEG by Lea Antonia Frey (9521468)

“…The best cross-validated PLSR model explained 56% of the measured variation and yielded a root mean square error (RMSE) of 17 mg g^–1 DW. …”

Species justification by discipline, in decreasing order of justifiability for students. by Eric P. Sandgren (7542725)

Descriptive analysis of antibodies concentrations by Elecsys Anti-SARS-CoV-2 S and EliA SARS-CoV-2-Sp1 IgG in the 256 non-infected volunteers included in the study. by Antonio Fernández-Suárez (14053814)

Decreased number of PDCs in blood during acute HFRS. by Saskia Scholz (4167784)

OPJ: Origin data for Fig 9a. by Nacer Badi (14046883)

“…Thermal and dynamic flow patterns are analyzed for a variety of parameters: Rayleigh numbers from 10² to 10⁶, PV panel tilt angle from 15° to 90°, and channel aspect ratios from 1/20 to 1/5. …”

OPJ: Origin data for Fig 7a. by Nacer Badi (14046883)

“…Thermal and dynamic flow patterns are analyzed for a variety of parameters: Rayleigh numbers from 10² to 10⁶, PV panel tilt angle from 15° to 90°, and channel aspect ratios from 1/20 to 1/5. …”

OPJ: Origin data for Fig 3a. by Nacer Badi (14046883)

“…Thermal and dynamic flow patterns are analyzed for a variety of parameters: Rayleigh numbers from 10² to 10⁶, PV panel tilt angle from 15° to 90°, and channel aspect ratios from 1/20 to 1/5. …”

OPJ: Origin data for Fig 6a. by Nacer Badi (14046883)

“…Thermal and dynamic flow patterns are analyzed for a variety of parameters: Rayleigh numbers from 10² to 10⁶, PV panel tilt angle from 15° to 90°, and channel aspect ratios from 1/20 to 1/5. …”

OPJ: Origin data for Fig 8a. by Nacer Badi (14046883)

“…Thermal and dynamic flow patterns are analyzed for a variety of parameters: Rayleigh numbers from 10² to 10⁶, PV panel tilt angle from 15° to 90°, and channel aspect ratios from 1/20 to 1/5. …”

OPJ: Origin data for Fig 2a. by Nacer Badi (14046883)

“…Thermal and dynamic flow patterns are analyzed for a variety of parameters: Rayleigh numbers from 10² to 10⁶, PV panel tilt angle from 15° to 90°, and channel aspect ratios from 1/20 to 1/5. …”

OPJ: Origin data for Fig 4a. by Nacer Badi (14046883)

“…Thermal and dynamic flow patterns are analyzed for a variety of parameters: Rayleigh numbers from 10² to 10⁶, PV panel tilt angle from 15° to 90°, and channel aspect ratios from 1/20 to 1/5. …”

eATP stimulation of RA decreased endothelial function. by Padmini Komalavilas (402160)

Functional effects of a Cdk5 inhibitor and/or GSK-3β inhibitor on the survival of pINT-EGFP cells. by Wen-Ching Lee (141923)

“…A decrease in caspase-3 BDP levels was also seen with Ros treatment (70.35±14.42% versus untreated cells; n = 6, p<0.05). …”

Inhibition of lp-PLA2 decreases the atherosclerotic area. by Wen-yi Wang (207256)

Image4_Vaccine induced mucosal and systemic memory NK/ILCs elicit decreased risk of SIV/SHIV acquisition.jpeg by Mohammad Arif Rahman (8267352)

“…<p>SIV and HIV-based envelope V1-deleted (ΔV1) vaccines, delivered systemically by the DNA/ALVAC/gp120 platform, decrease the risk of mucosal SIV or SHIV acquisition more effectively than V1-replete vaccines. …”

Image2_Vaccine induced mucosal and systemic memory NK/ILCs elicit decreased risk of SIV/SHIV acquisition.jpeg by Mohammad Arif Rahman (8267352)

“…<p>SIV and HIV-based envelope V1-deleted (ΔV1) vaccines, delivered systemically by the DNA/ALVAC/gp120 platform, decrease the risk of mucosal SIV or SHIV acquisition more effectively than V1-replete vaccines. …”

Image6_Vaccine induced mucosal and systemic memory NK/ILCs elicit decreased risk of SIV/SHIV acquisition.jpeg by Mohammad Arif Rahman (8267352)

“…<p>SIV and HIV-based envelope V1-deleted (ΔV1) vaccines, delivered systemically by the DNA/ALVAC/gp120 platform, decrease the risk of mucosal SIV or SHIV acquisition more effectively than V1-replete vaccines. …”